Nebenwirkungen · Xiliarx
Xiliarx 50 mg tablets · Abschnitt 4.8 · PDF-Seite 7
HOS-210547 · Präparat HOS-154539
Hepatic impairment Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to 24 weeks in duration, the incidence of ALT or AST elevations 3x ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg twice daily and all comparators, respectively. These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-05T16:30:00Z · SHA-256 c3c779825defe3cdfa205addcc4b8b8a94be37db71677d7ad8fe56f9ecb64ea0 · Passage df13c1185b104c6b3768793c1bb03e190a111bfe275c25e509b0d235f5c9c139 · Zeichen 4679–5432 im Abschnitt